Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Lagergren, E. Smyth, D. Cunningham, P. Lagergren (2017)
Oesophageal cancerThe Lancet, 390
J. Shapiro, J. Lanschot, M. Hulshof, P. Hagen, M. Henegouwen, B. Wijnhoven, H. Laarhoven, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp, M. Cuesta, R. Blaisse, O. Busch, F. Kate, G. Creemers, C. Punt, J. Plukker, H. Verheul, E. Bilgen, H. Dekken, M. Sangen, T. Rozema, K. Biermann, J. Beukema, A. Piet, C. rij, J. Reinders, H. Tilanus, E. Steyerberg, A. Gaast (2015)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.The Lancet. Oncology, 16 9
P. Hagen, M. Hulshof, J. Lanschot, E. Steyerberg, M. Henegouwen, B. Wijnhoven, D. Richel, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp, M. Cuesta, R. Blaisse, O. Busch, F. Kate, G. Creemers, C. Punt, J. Plukker, H. Verheul, E. Bilgen, H. Dekken, M. Sangen, T. Rozema, K. Biermann, J. Beukema, A. Piet, C. rij, J. Reinders, H. Tilanus, A. Gaast (2012)
Preoperative chemoradiotherapy for esophageal or junctional cancer.The New England journal of medicine, 366 22
K. Sjoquist, Fracp, R. Simes, Gebski Mstat, Alexandra Hospital, A. Brisbane, Peter Brisbane, Cancer Maccallum, Centre, V. Gebski, K. Sjoquist, B. Burmeister, M. Smithers, J. Zalcberg, J. Simes, A. Barbour (2011)
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.The Lancet. Oncology, 12 7
C. Willett, G. Warland, J. Coen, P. Shellito, C. Compton (1995)
Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation.International journal of radiation oncology, biology, physics, 32 1
Y. Kitagawa, T. Uno, T. Oyama, Ken Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, Masahiro Yoshida (2018)
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1Esophagus, 16
Han Yang, Hui Liu, Yu-ping Chen, Chengchu Zhu, W. Fang, Zhentao Yu, W. Mao, J. Xiang, Yongtao Han, Zhijian Chen, Haihua Yang, Jia-ming Wang, Q. Pang, Xiao Zheng, Huan-jun Yang, Tao Li, F. Lordick, X. D'Journo, R. Cerfolio, R. Korst, N. Novoa, S. Swanson, A. Brunelli, M. Ismail, H. Fernando, Xu Zhang, Qun Li, Gen-jie Wang, Baofu Chen, T. Mao, M. Kong, Xufeng Guo, Ting Lin, Mengzhong Liu, J. Fu (2018)
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical TrialJournal of Clinical Oncology, 36
G. Döbeln, F. Klevebro, A. Jacobsen, H. Johannessen, N. Nielsen, G. Johnsen, I. Hatlevoll, N. Glenjen, S. Friesland, L. Lundell, J. Yu, M. Nilsson (2018)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 32 2
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray (2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 71
Kenichi Nakamura, Ken Kato, H. Igaki, Yoshinori Ito, J. Mizusawa, N. Ando, H. Udagawa, Y. Tsubosa, H. Daiko, S. Hironaka, H. Fukuda, Y. Kitagawa (2013)
Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).Japanese journal of clinical oncology, 43 7
M. Stahl, M. Walz, M. Stuschke, N. Lehmann, H. Meyer, J. Riera-Knorrenschild, P. Langer, R. Engenhart-Cabillic, M. Bitzer, A. Königsrainer, W. Budach, H. Wilke (2009)
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 6
B. Noordman, M. Spaander, R. Valkema, B. Wijnhoven, M. Henegouwen, J. Shapiro, K. Biermann, A. Gaast, R. Hillegersberg, M. Hulshof, K. Krishnadath, S. Lagarde, G. Nieuwenhuijzen, L. Oostenbrug, P. Siersema, E. Schoon, M. Sosef, E. Steyerberg, J. Lanschot, Michael Doukas, N. Krak, J. Poley, C. rij, J. Bergman, S. Gisbertz, H. Laarhoven, S. Meijer, L. Goense, N. Mohammad, Monique Hobbelink, G. Offerhaus, F. Vleggaar, W. Curvers, G. Creemers, M. Roef, M. Sangen, J. Buijsen, Robert Riedl, W. Schreurs, Fabienne Warmerdam, Mjr Janssen, C. Post, S. Radema, C. Rosman, H. Rütten (2018)
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.The Lancet. Oncology, 19 7
B. Noordman, B. Wijnhoven, S. Lagarde, J. Boonstra, P. Coene, J. Dekker, M. Doukas, A. Gaast, J. Heisterkamp, E. Kouwenhoven, G. Nieuwenhuijzen, J. Pierie, C. Rosman, J. Sandick, M. Sangen, M. Sosef, M. Spaander, R. Valkema, E. Zaag, E. Steyerberg, J. Lanschot, B. v, B. Noordman, J. Lanschot, S. Lagarde, B. Wijnhoven, K. Biermann, A. Gaast, E. Ista, N. Krak, J. Nuyttens, S. Polinder, M. Spaander, E. Steyerberg, R. Valkema, A. Agool, J. Baarlen, E. Hendriksen, R. Hoekstra, E. Kouwenhoven, A. Linde, A. Bartels-Rutten, J. Dieren, J. Sandick, P. Snaebjornsson, E. Vegt, F. Voncken, H. Doornewaard, G. Erkelens, G. Madretsma, E. Zaag, M. Broek, R. Dallinga, J. Dekker, V. Dezentjé, R. Krijger, K. Neelis, R. Quispel, G. Creemers, G. Nieuwenhuijzen, M. Sangen, E. Schoon, D. Wyndaele, J. Buijsen, R. Riedl, W. Schreurs, M. Sosef, L. Oostenbrug, F. Warmerdam, J. Boonstra, M. Slingerland, W. Steur, I. Lips, W. Fiets, K. Linde, J. Nieken, V. Oppedijk, J. Pierie, R. Wolf, P. Coene, I. Butaihi, M. Kliffen, E. Kuiper, E. Staal, M. Janssen, M. Liedenbaum, C. Post, S. Radema, C. Rosman, H. Rütten, P. Siersema, L. Beerepoot, W. Hazen, J. Heisterkamp, J. Oord, T. Rozema, I. Vermeltfoort, A. Wurff (2018)
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBMC Cancer, 18
K. Kumagai, I. Rouvelas, J. Tsai, D. Mariosa, F. Klevebro, M. Lindblad, W. Ye, L. Lundell, M. Nilsson (2014)
Meta‐analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro‐oesophageal junctional cancersBritish Journal of Surgery, 101
H. Saeki, M. Sohda, M. Sakai, A. Sano, K. Shirabe (2020)
Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinomaAnnals of Gastroenterological Surgery, 4
D. Girling (2002)
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 359
N. Fan, Zhefang Wang, Chenghui Zhou, M. Bludau, G. Contino, Yue Zhao, C. Bruns (2021)
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysisEClinicalMedicine, 42
F. Klevebro, G. Döbeln, N. Wang, G. Johnsen, A. Jacobsen, S. Friesland, I. Hatlevoll, N. Glenjen, P. Lind, J. Tsai, L. Lundell, M. Nilsson (2016)
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.Annals of oncology : official journal of the European Society for Medical Oncology, 27 4
B. Burmeister, Janine Thomas, E. Burmeister, E. Walpole, J. Harvey, D. Thomson, A. Barbour, A. Barbour, D. Gotley, D. Gotley, B. Smithers, B. Smithers (2011)
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.European journal of cancer, 47 3
A. Fyles, A. Fyles, Michael Milosevic, Michael Milosevic, Raimond Wong, Raimond Wong, Mary-Claire Kavanagh, Melania Pintilie, Alex Sun, William Chapman, W. Levin, W. Levin, L. Manchul, L. Manchul, Thomas Keane, Thomas Keane, Richard Hill, Richard Hill (1998)
Oxygenation predicts radiation response and survival in patients with cervix cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 48 2
Xin Zhao, Yiming Ren, Yong Hu, N. Cui, Ximo Wang, Yunfeng Cui (2018)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trialsPLoS ONE, 13
Y. Kitagawa, T. Uno, T. Oyama, Ken Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, Masahiro Yoshida (2018)
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2Esophagus, 16
H. Kikuchi, H. Endo, H. Yamamoto, S. Ozawa, H. Miyata, Y. Kakeji, H. Matsubara, Y. Doki, Y. Kitagawa, H. Takeuchi (2021)
Impact of Reconstruction Route on Postoperative Morbidity After Esophagectomy: Analysis of Esophagectomies in the Japanese National Clinical DatabaseAnnals of Gastroenterological Surgery, 6
Y. Kitagawa, S. Matsuda (2020)
Prevention of postoperative pulmonary complication is desired to reduce mortality and improve long‐term survival after esophagectomy for esophageal cancerAnnals of Gastroenterological Surgery, 4
D. Cunningham, W. Allum, S. Stenning, J. Thompson, C. Velde, M. Nicolson, J. Scarffe, F. Lofts, S. Falk, T. Iveson, David Smith, R. Langley, M. Verma, S. Weeden, Y. Chua, MAGIC Participants (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.The New England journal of medicine, 355 1
T. Djärv, J. Lagergren, J. Blazeby, P. Lagergren (2008)
Long‐term health‐related quality of life following surgery for oesophageal cancerBritish Journal of Surgery, 95
K Kato (2022)
238J Clin Oncol, 40
D. Carter (1998)
TNM Classification of Malignant TumorsThe American Journal of Surgical Pathology, 22
N. Ando, H. Kato, H. Igaki, M. Shinoda, S. Ozawa, H. Shimizu, Tsutomu Nakamura, H. Yabusaki, N. Aoyama, A. Kurita, K. Ikeda, T. Kanda, T. Tsujinaka, Kenichi Nakamura, H. Fukuda (2011)
A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 19
Tnm (1988)
The tnm classification of malignant tumors, 26
B. Eyck, J. Lanschot, M. Hulshof, B. Wilk, J. Shapiro, P. Hagen, M. Henegouwen, B. Wijnhoven, H. Laarhoven, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp, M. Cuesta, R. Blaisse, O. Busch, G. Creemers, C. Punt, J. Plukker, H. Verheul, E. Bilgen, M. Sangen, T. Rozema, F. Kate, J. Beukema, A. Piet, C. rij, J. Reinders, H. Tilanus, E. Steyerberg, A. Gaast (2021)
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS TrialJournal of Clinical Oncology, 39
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
H. Shinozaki, T. Matsuoka, S. Ozawa (2021)
Pharmacological treatment to reduce pulmonary morbidity after esophagectomyAnnals of Gastroenterological Surgery, 5
BackgroundAlthough neoadjuvant treatment has become the standard of care for patients with locally advanced esophageal cancer, previous studies comparing neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) have demonstrated inconclusive results.MethodsOur study cohort included 3978 patients from 85 institutions. Those who underwent NAC or NACRT followed by surgery for esophageal squamous cell carcinoma (ESCC) were eligible for inclusion. We used the inverse probability of treatment weighting (IPTW) method to compare the outcomes between NAC and NACRT.ResultsAmong the 3978 patients, 3777 (94.9%) received NAC and 201 (5.1%) received NACRT. After IPTW adjustment, the NACRT group had more patients with pathologically downstaged diseases and significantly better pathological response compared with the NAC group (p < 0.001); however, 5-year overall survival (OS), recurrence-free survival (RFS), and regional recurrence-specific survival (RRSS) were comparable between the groups. Subgroup analysis stratifying patients according to cT category showed that among cT1-2 patients, those in the NACRT group had significantly longer 5-year OS, RFS, and RRSS than those in the NAC group (P = 0.024, < 0.001, and 0.020, respectively). In contrast, no significant differences were observed among cT3-4a patients. The competing risks regression model showed comparable subdistribution hazard ratios for 10-year cancerous and noncancerous deaths between the NAC and NACRT groups.ConclusionsCompared with NAC, NACRT for ESCC did not promote better survival despite better therapeutic effects and did not increase noncancerous deaths.
Annals of Surgical Oncology – Springer Journals
Published: Sep 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.